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Abstract: Asthma with bronchial hypersecretion is a type of asthma that is poorly studied. 
Its pathogenesis is not well understood, but is probably related to innate impaired immunity, 
particularly with toll-like receptors (TLRs) and secretory mucins (MUC).
Objectives: 1) Define the clinical and inflammatory phenotype of asthma with bronchial 
hypersecretion of mucus. 2) Compare the type of mucin present in induced sputum (IS) of 
patients with and without bronchial hypersecretion. 3) Determine the expression of TLRs in IS 
and blood of asthmatics with and without bronchial hypersecretion.
Materials and methods: Cross-sectional study which included 43 non-smoking asthmatic 
patients without bronchiectasis, 19 with bronchiectasis, and 24 without bronchial hypersecre-
tion. All patients underwent the following: IS, spirometry, fractional exhaled nitric oxide, prick 
test, total immunoglobulin E (IgE), and blood albumin. Analysis of mucins was determined by 
ELISA and expression of TLR2 and TLR4 by flow cytometry. The level of asthma control was 
determined by the Asthma Control Test (ACT) questionnaire and quality of life was assessed 
by the reduced version of the Asthma Quality of Life Questionnaire (mini-AQLQ).
Results: Asthmatics with bronchial hypersecretion were significantly older (62.6 years vs 48.5 
years; p=0.02); had greater severity (persistent severe asthma 94.7% vs 29.2%; p=0.000); a 
higher proportion of nasal polyposis (36.8% vs 8.3%; p=0.022); less control of asthma (73.7% 
vs 8.3%; p=0,000); a higher proportion of asthma with negative prick test (68.4% vs 16.6%; 
p=0.001), and lower levels of IgE (113.4 IU/mL vs 448 IU/mL; p=0.007), compared with 
asthmatics without bronchial hypersecretion. Significant differences were observed neither 
in the expression of  TLRs 2 and 4 in inflammatory cells of IS or peripheral blood, nor in the 
expression of mucins between both groups.
Conclusion: Asthma patients with bronchial hypersecretion have more severe and uncontrolled 
disease, with poor quality of life as well as a non-allergic inflammatory phenotype. Within 
the mechanisms involving these differences, it does not appear that mucins and TLRs play an 
important role.
Keywords: asthma, mucins, inflammation, induced sputum, toll-like receptor
Introduction
Bronchial inflammation in asthmatic patients with chronic airflow obstruction and 
bronchial hypersecretion, superimposed on phenotype 5 of diseases of the airway 
described by Weatherall et al,1 differs from the usual classic allergic eosinophilic 
asthma. However, available information about this type of asthma is scarce. It is well 
known that the mucus of asthmatic patients is characterized by its higher viscosity and 
may play an important role in the pathogenesis of the obstruction that accompanies 
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the disease and in fatal asthma attacks. Some studies have 
reported that this could be related to the different mucin 
profile (ie, MUC2, MUC5B>MUC5A, MUC5AC) that 
these patients present.2–4 However, it is unknown whether 
the profile of mucins secreted by asthmatic patients with 
bronchial hypersecretion differs from those of asthmatics 
not suffering from bronchial mucus hypersecretion. Mucins 
(MUC) are glycoproteins that are part of airway mucus; they 
are responsible of its viscoelastic properties and play an 
important antimicrobial and anti-inflammatory role, acting 
as a first line of immunological defence.5 MUC are composed 
of alpha and beta subunits and form a complex heterodimer. 
The alpha subunit acts in cell adhesion, and the beta unit in 
cellular signaling. Increasingly, the beta subunit is related 
to the activation of so-called toll-like receptors (TLRs). 
TLRs are a family of trans-membrane proteins responsible 
for the recognition of pathogen-associated molecular pat-
terns, molecules characteristic of microorganisms such as 
lipopolysaccharides, flagellins, mannans, or nucleic acids of 
viruses and bacteria. This recognition leads to rapid produc-
tion of cytokines, providing an adaptive and lasting response 
against the pathogen.6 The relationship between bronchial 
hypersecretion, mucins, and activation of TLRs would open 
a new field in the pathogenesis of this form of the disease, 
as it would establish a relationship of innate immunity and 
respiratory infections with bronchial hypersecretion.
It is known that bronchial mucus hypersecretion leads 
to impaired mucociliary clearance and abnormal bacterial 
implantation, and promotes mucus plugs in the airways.7 
Despite these characteristics observed in the clinical follow-
up of some asthma patients, few studies have included this 
variant of asthma, and none have studied the distinguishing 
characteristics of these patients. Morinaga et al and Kraft 
et al associated infections with bronchial hypersecretion, 
demonstrating increased mucin production (MUC5AC) in 
cultured epithelial cells of asthmatic patients when stimulated 
by Chlamydia and M. pneumoniae.8,9 They also showed that 
mucin production decreased when they exposed bronchial 
epithelial cells to macrolide9 and that the effect (in the case 
of M. pneumoniae infection) disappears when TLR-2 and 
an NF-KB inhibitor are added.10 This fact implicates TLR-2 
in the initial inflammatory response leading to exacerba-
tions of asthma produced by M. pneumoniae and relates 
TLRs to mucins.10,11 In the same vein, another study recently 
showed that MUC1 specifically plays a role during inflam-
matory bacterial infection of the airways, not only because 
of TLR-5 signal suppression,12 but also because it involves 
other TLRs, such as 2, 3, 4, 7, and 9.12 It is suspected that 
MUC1, in  addition to suppressing the activation of NF-KB 
(at the TRAF6–TAK1 complex level), can stimulate TLRs 
signaling.13
This study had the following objectives: 1) Define the 
clinical and inflammatory phenotype of asthma with bron-
chial hypersecretion of mucus. 2) Compare the type of mucin 
present in induced sputum (IS) of patients with and without 
bronchial hypersecretion. 3) Determine the expression of 
TLRs in the IS and in the peripheral blood of asthmatics with 
and without bronchial hypersecretion.
Materials and methods
study design 
This cross-sectional study carried out in a tertiary referral 
university hospital in Barcelona, Spain. The aim of the study 
was to define the clinical and inflammatory phenotype of 
asthma with bronchial hypersecretion of mucus, compare 
the types of mucin present in IS in patients with and without 
bronchial hypersecretion, and determine the expression of 
TLRs in the IS and peripheral blood between the two groups. 
subjects
Male and female subjects aged >18 years, non-smokers, 
without bronchiectasis, who fulfilled the diagnostic criteria 
of asthma were consecutively enrolled from the Asthma 
Unit outpatient clinic of our institution. We defined asthma 
as a history of variable respiratory symptoms with evidence 
of variable expiratory airflow limitation. All patients had a 
positive bronchodilator test or a positive methacholine chal-
lenge test documented in the case history. Asthma severity 
was defined according to the Global Initiative for Asthma 
Management (GINA).14 All patients included in the study 
underwent a chest computed tomography (CT), in which the 
presence of bronchiectasis or other non-asthmatic pathol-
ogy was ruled out (lung cancer, pulmonary tuberculosis, 
sarcoidosis, nephropathy, and rheumatic or liver disease). 
Moreover, patients were excluded from the study if they 
had a respiratory tract infection and/or required the use of 
oral corticosteroids within 30 days prior to inclusion; had a 
significant comorbidity that could affect the study results in 
the physician’s judgment; or had a cognitive impairment that 
could limit their comprehension of the subject under study 
or their ability to participate.
Ethics approval and consent to 
participate
This study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki (18th World Medical 
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Assembly) and was approved by the Independent Ethics 
Committee of Hospital de la Santa Creu i Sant Pau (approval 
number COD:IIBS-ROF-2011-106). All patients gave writ-
ten informed consent to participate in the study. Subjects 
were included upon receipt of written informed consent and 
personal identification data were anonymized. ClinicalTrials.
gov Identifier: NCT02948153. Registered October 18, 2016. 
Retrospectively registered.
Assessments and study procedures
In 43 asthmatic patients, demographic and clinical variables 
were recorded. On the same day, the following determinations 
or tests were performed: FeNO, forced spirometry, inflamma-
tory cell count in IS, serum total IgE levels, eosinophil count 
in the peripheral blood, and skin prick test to common aeroal-
lergens in our environment. Patients also completed a Spanish 
validated version of the Asthma Control Test (ACT)15 and the 
reduced version of the Asthma Quality of Life Questionnaire 
(mini-AQLQ).16 Asthmatics patients with bronchial hypersecre-
tion were defined as those who expectorated daily for at least 3 
months for a minimum period of two consecutive years, without 
attribution to any other cause or disease. All patients underwent 
microscopic analysis of IS, and the presence of associated bac-
teria in the sputum was ruled out (exclusion criterion).
FeNO was measured before spirometry using electro-
chemical equipment (NO Vario Analyzer, Berlin, Germany) 
and an expiratory maneuver providing a sustained 50 mL/s 
flow from total lung capacity, according to the 2005 recom-
mendations of the American Thoracic Society/European 
Respiratory Society (ERS).17 A significant increase in FeNO 
was considered if the FeNO value was equal or higher than 
50 parts per billion (ppb).18 Spirometry was undertaken 
using a Daptospir-600 spirometer (Sibelmed, Barcelona, 
Spain) by an experienced pulmonary function technician 
and according to the 2003 recommendations of the Spanish 
Society of Pneumology and Thoracic Surgery (SEPAR),19 
with FEV
1
 in the reference range when ≥80% predicted.20 
IS samples were harvested according to ERS consensus 
protocol21 and processed for flow cytometry and conventional 
readouts.22 Briefly, mucus plugs were manually selected and 
homogenized in 0.1% dithiothreitol (DTT; Calbiochem, 
San Diego, CA, USA) for 15 min, then washed and filtered 
through a 41-μm pore nylon mesh (Millipore, Membrane 
solutions, Dallas, TX, USA). Cell viability and quality were 
determined by trypan blue exclusion dye. Samples with less 
than 106 cells/g, less than 40% viability, and greater than 20% 
squamous epithelial cells were excluded. Slides with 5×104 
cells were stained with Diff-Quik kit (Polysciences Europe 
GmbH, Eppelheim, Germany), Cell count and differential 
leukocyte count were done following references that were 
previously established.23 We suspended 106 sputum cells in 1 
mL staining buffer [3% bovine serum albumin in phosphate-
buffered saline (PBS)] and delivered into a 100-μL tube for 
flow cytometry analysis. Patients with a neutrophil count 
≥61% were classified as having neutrophilic asthma, those 
with eosinophil sputum count ≥3% as eosinophilic asthma, 
those with a neutrophil count <61% and a eosinophil sputum 
count <3% as paucigranulocytic asthma, and those with a 
neutrophil count ≥61% and a eosinophil sputum count ≥3% 
as mixed asthma.24 
Serum total IgE was measured by ImmunoCAP using 
the UniCAP 250 system (Phadia AB, Uppsala, Sweden), 
with increased levels for values >160 IU/mL. Skin prick 
testing was conducted according to a standard procedure, 
with positive results when the wheal diameter was >3 mm.25 
The 100-μL sample of peripheral blood was immunostaining 
for flow cytometry and erythrolysed with TQ Prep Sample 
Preparation and COULTER PrepPlus 2 (Beckman Coulter, 
Miami, FL, USA).
To objectively assess the level of asthma control, we 
used the ACT. This is a simple, five-item questionnaire 
that measures the degree of control of the asthmatic patient 
assigned to their illness over the last 4 weeks. The answers 
for each question are assigned 1–5 points, resulting in a 
total score ranging from 5 (worst possible control) to 25 (the 
best possible control). A score more than 20 corresponds to 
“controlled asthma,” and less than 19 points to “not well-
controlled asthma.”15 High doses of inhaled steroids were 
considered as beclomethasone dipropionate (or equivalent) 
≥1,000 μg/day.26 To determine the quality of life related to 
asthma, we used the mini-AQLQ.16
Analysis of mucin by elisA
Mucin levels were determined by Enzyme Linked Immuno-
sorbent Assay (ELISA), following manufacturer’s instruc-
tions. MUCIN 1 and MUCIN 5B were purchased from 
Wuxi Donglin Sci&Tech Development Co., Ltd., MUCIN 2 
was purchased from Elabscience Biotechnology Co., Ltd., 
and MUCIN 5AC was purchased from Life Science Inc. 
MUCIN detection ranges were MUC 1 (0.15–10 ng/mL), 
MUC2 (0.313–20 ng/mL), MUC5AC (78–5,000 pg/mL), 
and MUC5B (0.625–40 ng/mL).
TLRs analysis by flow cytometry
Blood and sputum cells were blocked with mouse serum 
and immunostained with anti-TLR4 PE (clone HTA125), 





anti-CD66b PE (G10f5), and anti-CD14 PE/Cy7 (clone 
M5E2) from Biolegend (San Diego, CA, USA); anti-TLR2 
Alexa Fluor 488 (clone 11G7) and anti-CD125 PE (A14) 
from BD Biosciences (Eembodegen, Belgium); and anti-
CD16 PE (3G8), anti-CD45 PE (MEM28), anti-CD16 FITC 
(3G8), anti-CD66b FITC (B13.9), and anti CD45 PE/Dy-647 
(MEM28) from Immunotools (Oldenburg, Germany).22 
Samples were incubated in the dark for 15 min at room tem-
perature. Then, cells were washed with 2 mL staining buffer 
and centrifuged for 5 min at 1,750 rpm. Supernatants were 
decanted, the cells resuspended in 300 μL staining buffer, and 
the samples were stored at 4°C in the dark until analysis on 
the flow cytometer within 2 h from preparation.
Flow cytometric data acquisition was performed with 
the FC500 equipment (Beckman Coulter, Pasadena, CA, 
USA). Ten thousand events were counted for all sample 
runs. Gating for discrimination of leukocytes was based on 
CD45 expression versus side-light scatter. The mean fluo-
rescence intensity (MFI) of the cells stained with control 
antibody was subtracted from the MFI of the cells stained 
with receptor antibodies to provide a measure of receptor-
specific fluorescence.
statistical analysis
Categorical variables were expressed as frequencies and 
percentages, and continuous variables as mean and standard 
deviation (SD). Comparisons between both groups were 
undertaken with the Student’s t test for quantitative variables 
and the chi-square (χ2) test or the McNemar’s test for cat-
egorical variables. Statistical significance was set at p <0.05. 
Statistical analysis was conducted with SPSS version 18.0 
for Windows (Chicago, IL, USA).
Results
clinical phenotypes of asthmatics 
patients with and without bronchial 
hypersecretion
Compared to the non-hypersecretory group, hypersecretory 
asthmatics patients were older, had greater disease severity, 
increased bronchial obstruction, greater use of high doses of 
inhaled steroids, a higher proportion of nasal polyposis, less 
control of asthma, lower score on the MiniAQLQ, a greater 
number of emergency room visits in the previous year, a 
greater need for short courses of oral corticosteroids in the 
previous year, a higher proportion of asthma with negative 
prick test, lower levels of IgE, lower albumin levels in periph-
eral blood, and lower levels of lymphocytes in IS (Table 1).
inhaled treatment
In the asthma group with bronchial hypersecretion, 21% 
used budesonide and formoterol; 52.6% used fluticasone and 
salmeterol; and 26.4% used beclomethasone and formoterol. 
In the asthma group without bronchial hypersecretion, 12.5% 
used budesonide and formoterol; 20.8% used fluticasone and 
salmeterol; 33.3% used beclometasone and formoterol; and 
33.4% only received salbutamol (p=0.018). On the other 
hand, 47.36% of asthma patients with bronchial hypersecre-
tion had anticholinergics associated as maintenance treat-
ment. None of the non-hypersecretors had this treatment. 
The difference between the two groups is due to the greater 
severity of the disease that asthma patients with bronchial 
hypersecretion experience.
Mucin expression
Mean mucin expression of all asthmatics patients (N=43) 
was MUC1: 114.72 ng/mL (standard deviation [SD] 59.30); 
MUC2: 24.42 ng/mL (SD 19.75); MUC5AC: 456.18 pg/mL 
(SD 1123.3); and MUC5B: 1.24 ng/mL (SD 4.04). Thus, in 
all asthmatics patients in the study (N=43), MUC 1 was very 
high, followed by MUC 2; however, MUC5AC and MUC 5B 
were within the reference values (see the section on mucin 
detection ranges in the analysis of mucin by ELISA).
The expression of mucins MUC1, MUC2, MUC5AC, 
and MUC5B in patients with and without bronchial hyper-
secretion is shown in Table 2. No significant differences in 
levels of mucin present in IS were observed between the two 
groups of asthmatic patients studied. However, higher levels 
of MUC5AC and lower levels of MUC5B were observed in 
patients with bronchial hypersecretion in comparison with 
asthmatics without bronchial hypersecretion but without 
significant differences (probably, due to the large SD of the 
values of this mucin). Mucin levels were not correlated with 
variables such as age, body mass index (BMI), total blood IgE 
levels, percentage of eosinophils in blood and sputum, and 
FeNO levels. A positive correlation between MUC 2 levels 
and FEV
1
% (r=0.360; p=0.003) was found in all patients.
expression of Tlrs 2 and 4 in asthmatic 
patients with and without bronchial 
hypersecretion
Expression of TLRs 2 and 4 in macrophages and neutrophils 
of IS and peripheral blood in asthmatic patients with and 
without bronchial hypersecretion is detailed in Table 2. No 
significant differences were observed between groups in the 
expression of these receptors in inflammatory cells in the 
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sputum or peripheral blood. A higher intensity of TLR-4 
fluorescence was observed in monocytes [2.04 MFI (1.06) vs 
1.2 MFI (0.63); p=0.003] and in peripheral blood neutrophils 
[2.34 MFI (0.53) vs 1.68 MFI (0.66); p=0.000] of hypersecre-
tory patients versus non-hypersecretors.
Discussion
The main results of the present study were: first, asthmatic 
patients with bronchial hypersecretion had clinical features 
different from those without bronchial hypersecretion. Sec-
ond, mucin expression in IS of these patients did not differ 
from those who did not present with bronchial hypersecretion. 
Third, innate immunity, specifically TLRs 2 and 4, did not 
seem to be involved in the differences between these patients.
Bronchial hypersecretion is a subject that is rarely 
included as a factor of poor prognosis in patients with asthma 
and, therefore, few studies consider this variable in patients.1 
In this study, asthmatic patients with bronchial hypersecre-
tion were characterized by older age, greater severity of 
asthma, more emergency room visits and use of courses 
of oral corticosteroids for exacerbations, a greater degree 
of nasal polyposis, a non-allergic eosinophilic phenotype, 
poor control of the disease, and a poorer quality of life. This 
profile with more severe, non-allergic, eosinophilic asthma, 
with nasal polyposis could overlap with a type of eosinophilic 
asthma having a pathophysiological mechanism that is yet to 
be determined, and differs from typical allergic eosinophilic 
asthma mediated by a Th2 response. Based on these findings, 
Brusselle et al27 suggest two different roads leading to the 
eosinophilic inflammation of the airways in asthma. In the 
allergic type, the protagonist cells would be dendritic cells 
and CD4+ T cells, with the induction of Th2 cells and produc-
tion of IL-4, -5, and -13. In non-allergic eosinophilic type, 
pollution, microbes, and glycolipids could induce the release 
of cytokines derived from the epithelium, including IL-33, 
IL-25, and TSLP (epithelial cytokine of the thymic stromal 
lymphopoietin), which would increase the number of group 
2 innate lymphoid cells (ILC2s) in an antigen-dependent 
manner through their respective receptors (IL-17RB, ST2, 
and TSLP). Activation of the ILC2s would produce high 
amounts of IL-5 and IL-13, which in turn would lead to 
eosinophilia and airway hyperresponsiveness. Along the same 
lines, Wenzel,28 in an article published in Nature Medicine, 
describes patients who have asthma with persistent eosino-
philia despite receiving steroid treatment, and these patients 
were associated with greater disease severity, beginning in 
Table 1 Demographic, clinical, and functional characteristics of the patients studied
Asthma with bronchial 
hypersecretion
N=19




Age (years) mean (sD) 62.6 (10.7) 48.54 (16.9) 0.020
sex (female) % 73% 66% 0.437
BMi (kg/m2) 28.6 (3.4) 26.9 (4.7) 0.182
nasal polyposis (%) 36.8% 8.3% 0.022
Adult asthma diagnosis (%) 79% 54% 0.084
Patients with positive skin prick test (%) 31.6% 83.4% 0.001
Patients with AcT < 20 (%) 73.7% 8.3% 0.000
Mini-AQlQ, mean (sD) 4.04 (3.1) 1.95 (2.1) 0.023
number of visits to the er in the past 12 months, mean (sD) 3.6 (3.5) 1.5 (2.2) 0.020
number of courses of Oc received in the last 12 months, mean (sD) 4.2 (3.8) 0.75 (1.2) 0.001
Patients with beclomethasone (or equivalent ics) ≥ 800 µg/day (%) 78.94% 54.16% 0.047
severe asthma (%) 94.7% 29.2% 0.000
FeV1 (l), mean (sD) 1.84 (0.7) 2.54 (1.0) 0.013
FeV1/FVc %, mean (sD) 60.1 (13.4) 69.8 (8.1) 0.010
FenO (ppB), mean (sD) 32.74 (19.8) 37.37 (30.4) 0.556









Blood total ige (Ui/ml), mean (sD) 113.4 (173) 448 (536) 0.007
Blood albumin (g/l), mean (sD) 41 (2.7) 44 (2.3) 0.000
Notes: Values are mean ± standard deviation (SD) or percentage, as indicated. Bold figures represent p<0.05.
Abbreviations: AcT, Asthma control Test; BMi, body mass index; er, emergency room; FenO, exhaled nitric oxide fraction; FeV1, forced expiratory volume in first 
second; FVc, forced vital capacity; ics, inhaled corticosteroids; ige, total immunoglobulin e; mini-AQlQ, Asthma Quality of life Questionnaire; Oc, oral corticosteroids.





late age, little family history of asthma, intolerance at times 
to nonsteroidal anti-inflammatory drugs (NSAIDs), sinusitis, 
polyps, and a less allergic component (bronchial hypersecre-
tion was not assessed in this study). Lack of allergy in these 
patients suggests a different mechanism from Th2, and is 
probably more complex than the typical early-onset allergic 
phenotype.28 The results of our study were related to this 
profile of patients with characteristics presented in our work 
by asthmatic patients with bronchial hypersecretion – that 
is, patients with greater severity, older, more polyposis, and 
with an inflammatory phenotype predominantly eosinophilic, 
not allergic. These results, despite describing an asthma 
phenotype comparable to those mentioned previously in the 
literature, require further studies to confirm this relationship. 
In these studies, we propose the inclusion of the variable of 
bronchial hypersecretion of mucus in asthmatic patients in 
their analysis as a factor of worse prognosis.
Several studies have shown that the mucus of asthmatic 
patients shows greater viscosity than that of patients with 
chronic obstructive pulmonary disease (COPD) and cystic 
fibrosis (CF);3,29 in addition, they reported that this differ-
ence lies in the fact that they have a different mucin profile. 
MUCs are glycoproteins that are part of the airway mucus; 
they are responsible for its viscoelastic properties and play 
an important antimicrobial and anti-inflammatory role in 
acting as a first immunological line of defence.5 MUCs are 
composed of alpha and beta subunits that undertake cell 
adhesion and cellular signaling. In patients with COPD, 
MUCs present with elevated levels, specifically MUC5AC, 
MUC5B, and MUC 2, unlike in asthmatic patients where 
MUC5AC and MUC5B show values tending to normal and 
only a small amount of MUC2 is present.3,29 In our study, no 
significant differences were observed in the expression of 
mucin among asthmatic patients who did or did not  present 
Table 2 Mucins levels in induced sputum and expression of Tlrs 2 and 4 in asthmatic patients distributed in two groups according to 
the presence or absence of bronchial hypersecretion
Asthma with bronchial 
hypersecretion
N=19





MUc1 (ng/ml) 115.22 (45.1) 114.26 (71.5) 0.963
MUc2 (ng/ml) 21.66 (22.8) 27.04 (16.6) 0.429
MUc5Ac (ng/ml) 707.42 (1515.7) 189.25 (306.1) 0.185
MUc5B (ng/ml) 0.91 (2.6) 1.55 (5.1) 0.647
Expression of TLRs 2 and 4
Percentage of cells expressing Tlrs2
Monocytes (blood)
• cells (%) 77.84 (29.6) 72.91 (34.6) 0.625
• MFi 2.4 (1.1) 2.3 (1.3) 0.869
neutrophils (sputum)
• cells (%) 1.01 (1.1) 1.16 (1.5) 0.095
• MFi 2.19 (1.1) 2.63 (1.1) 0.642
Macrophages (sputum)
• cells (%) 27.44 (16.6) 17.12 (15.1) 0.944
• MFi 2.55 (1.8) 1.99 (0.9) 0.682
Percentage of cells expressing Tlrs4
neutrophils (blood)
• cells (%) 2.14 (1.3) 1.92 (2.5) 0.758
• MFi 2.34 (0.5) 1.68 (0.6) 0.002
Monocytes (blood)
• cells (%) 50.58 (23.3) 47.83 (25.8) 0.720
• MFi 2.04 (1.1) 1.2 (0.6) 0.003
neutrophils (sputum)
• cells (%) 3.24 (2.7) 7.84 (11.7) 0.098
• MFi 3.27 (1.7) 3.16 (0.9) 0.096
Macrophages (sputum)
• cells (%) 41.73 (20.8) 46.74 (19.6) 0.804
• MFi 5.54 (2.3) 8.14 (3.8) 0.072
Notes: Values are mean percentage and standard deviation (SD) for mucins and cell counts, and mean (SD) for MFI. Bold figures represent p<0.05.
Abbreviations: MUc, mucins; MFI, mean of fluorescence intensity; TLRs, toll-like receptors.
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with bronchial  hypersecretion, and taking both groups of 
asthmatic patients as a whole, the results agree with the 
literature, with the MUC1 being very high, followed by the 
MUC2 being slightly elevated, and MUC5AC and MUC5B 
being inside the reference values. On the other hand, it should 
be noted that we observed higher levels of MUC5AC and 
lower levels of MUC5B in patients with bronchial hyper-
secretion in comparison with asthmatics without bronchial 
hypersecretion (non-significant changes). Some reports have 
described technical difficulties in quantifying sputum mucins 
by direct-binding ELISAs due to high levels of nonmucin 
proteins that may interfere with the immobilization of the 
mucins on the plate30; this point may be a limitation for 
consideration in our study.
Recently, it has been shown that MUC1 plays an anti-
inflammatory role in bacterial infection of the airways, and 
this effect involves the participation of TLRs.17 It is suspected 
that the MUC1, in addition to suppressing the activation of 
NF-KB (at the TRAF6–TAK1 complex level), can stimu-
late these TLR signals. Thus, it is known that other signals 
(TLRs 2, 3, 4, 7, and 9) are also suppressed by MUC1. TLRs 
are responsible for the recognition of pathogen-associated 
molecular patterns; therefore, both proteins (MUC and TLRs) 
are involved primarily in local defense against respiratory 
infections. TLRs have been related to both neutrophilic and 
allergic asthma, specifically TLRs 2 and 4, and activation of 
TLRs.6 In our study, we found high levels of MUC1 expres-
sion in both groups of asthmatic patients, but no significant 
differences between the groups with and without bronchial 
hypersecretion were observed.
Our study has some limitations: 1) we did not purify 
mucins from nonmucin proteins, nor use cocktails of antibod-
ies to maximize epitope regnition;30 2) the effect of inhaled 
corticosteroids on expression of TLRs is unknown; 3) we only 
analyzed receptors that are expressed on the cell surface (TLRs 
4 and 2); 4) this was a descriptive study with a small sample 
of patients, but has several strengths as compared to previous 
reports. This was a comprehensive study in a large sample 
using multiple techniques to assess various aspects of the 
disease, whereas other studies to date have focused on specific 
or partial aspects. Furthermore, it is the first study measuring 
mucins and TLRs in the sputum of asthmatic patients and all 
the measurements were made on the same day in all patients 
(clinical, functional, and inflammatory variables).
Conclusion
In summary, we can conclude that asthmatic patients with 
bronchial hypersecretion have a more severe and uncontrolled 
disease, an inflammatory phenotype that is predominantly 
non-allergic, and present with a poor quality of life. Regard-
less of whether innate immunity plays a role in the patho-
genesis of this type of asthma with bronchial hypersecretion, 
the present study failed to demonstrate an abnormality in 
the mucin profile and in TLRs 2 and 4 in sputum and blood. 
Because this study shows that asthmatic patients with bron-
chial hypersecretion present with a poor prognosis, from a 
clinical standpoint, this variable should be elicited in the 
patient’s history.
Highlights
•	 Despite the clinical repercussions of bronchial mucus 
hypersecretion in the asthmatic patient, this variable has 
been poorly studied.
•	 To date, the relationship of innate immunity with the 
presence of bronchial mucus hypersecretion in asthmatic 
patients is unknown.
•	 TLRs and mucins play an important role in defense 
against pathogens. Several alterations of these proteins 
have been described as part of the pathophysiological 
mechanism of some asthma phenotypes.
•	 The possible recognition of a new endotype of asthma, 
mediated by the alteration of TLRs and mucins, especially 
in asthma with bronchial mucus hypersecretion, could 
open new therapeutic expectations, especially in a type 
of asthma with a traditional low response to conventional 
treatment of the illness.
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